Trademarkia Logo

Canada

C$
Trademark Search in Canada
GENERATION BIO & DESIGN

View On IC.GC.CA

GENERATION BIO & DESIGN
REGISTERED

on 18 May 2021

TM5 Status

LIVE/REGISTRATION/Issued and Active

Your registration has been issued and is active. You can now use the TM5 mark.

Last Applicant/ Owned by

GENERATION BIO CO.

301 Binney Street, Suite 401Cambridge, Massachusetts02142

US

Serial Number

1897867 filed on 7th May 2018

Registration Number

TMA1100313 registered on 18th May 2021

Registration expiry Date

18th May 2031

Correspondent Address

SMART & BIGGAR LP

SCOTIA PLAZA40 KING STREET WEST40th FLOORTORONTO

ONTARIO

CA

M5H3Y2

GENERATION BIO & DESIGN

Trademark usage description

pharmaceutical preparations and genetic medicines for the treatment of genetic disorders, genetic diseases, related diseases having a genetic cause or Read More

Classification Information

Class [005]
Pharmaceutical preparations and genetic medicines for the treatment of genetic disorders, genetic diseases, related diseases having a genetic cause or component and disease states resulting from gene expression or genetic sequence, namely, Hemophilia A, hemophilia B, cystic fibrosis, familial hypercholesterolemia, phenylketonuria, Wilson's disease, congenital hepatic porphyria, Lesch-Nyhan syndrome, Leber Congenital Amaurosis, Stargardt macular dystrophy, ornithine transcarbamylase deficiency, Usher syndrome, alpha-1 antitrypsin deficiency, progressive familial intrahepatic cholestasis types I, II, III, and IV, sickle cell anemia, thalassaemias, xeroderma pigmentosum, Fanconi's anemia, retinitis pigmentosa, macular degeneration, ataxia telangiectasia, Bloom's syndrome, retinoblastoma, Hurler syndrome, Scheie syndrome, Hurler-Scheie syndrome, Hunter syndrome, Sanfilippo Types A, B, C, and D, Morquio Types A and B, Maroteaux-Lamy syndrome, Sly syndrome, hyaluronidase deficiency, Niemann-Pick Disease Types A, B, C1 and C2, Fabry disease, Schindler disease, Sandhoff Disease, Tay-Sachs disease, Metachromatic Leukodystrophy, Krabbe disease, Mucolipidosis Type I, II, III and IV, Sialidosis Types I and II, glycogen storage disease Types I and II, Gaucher disease Types I, II and III, cystinosis, Batten disease, Aspartylglucosaminuria, Salla disease, Danon disease, Lysosomal Acid Lipase deficiency, Pompe disease, neuronal ceroid lipofuscinoses, sphingolipidosis, galactosialidosis, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, spinocerebellar ataxia, spinal muscular atrophy, Friedreich's ataxia, Duchenne muscular dystrophy, Becker muscular dystrophies, dystrophic epidermolysis bullosa, ectonucleotide pyrophosphatase 1 deficiency, generalized arterial calcification of infancy, and cathepsin A deficiency.

Classification kind code

11

Class [042]
Scientific and medical research relating to the diagnosis and/or treatment of genetic diseases and related diseases; product development and consultancy in the field of biotechnology, biologics, pharmaceutics, medical science, chemistry and biochemistry

Classification kind code

11

Class [044]
Providing information in the field of diagnosis and/or treatment of genetic diseases and related diseases; therapeutic gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of genetic diseases and related diseases, via website

Classification kind code

11

Mark Details

Serial Number

1897867

Mark Type

Trademark

Legal History

Show more

Action TakenStatus
Submitted for opposition 26
on 22nd Jan 2021		Approved
Submitted for opposition 23
on 18th Jan 2021		Default Removed
Submitted for opposition 14
on 6th Jan 2021		Default Notice Sent
Submitted for opposition 15
on 18th Jun 2020		Correspondence Created
Submitted for opposition 22
on 22nd Nov 2019		Search Recorded
Submitted for opposition 20
on 22nd Nov 2019		Examiner's First Report
Submitted for opposition 135
on 25th Sept 2019		Amendment to Application
Submitted for opposition 31
on 10th May 2018		Formalized
Submitted for opposition 1
on 9th May 2018		Created
Submitted for opposition 30
on 7th May 2018		Filed